5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Randomized Clinical Trial Protocol
Open Access
- 1 May 2025
- journal article
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 1 (1) , 19
Abstract
Background Surgeons provide up to 10% of total opioid prescriptions across all specialties, and more than one-third of surgeon-prescribed medications are opioids. Patient-reported opioid consumption and risk of persistent opioid use beyond the postoperative recovery period correlate with the initial opioid quantity prescribed at discharge. Interventions to reduce postoperative opioid prescribing have demonstrated no adverse effects on pain control or increased need for prescription refill; however, in the absence of standardized prescription protocols, opioid prescribing practices vary widely. Objective The study objective is to identify the opioid prescribing model that provides the lowest oral morphine equivalents (OME) volume prescribed at discharge and OME consumed in the 14 days after discharge, with no adverse effect on refills and patient quality of life or satisfaction. Methods and Analysis This is a pragmatic single-center, multispecialty, double-arm phase II randomized clinical trial of two discharge opioid prescribing models. All adult (≥18 years) patients who undergo any one of five open abdominal oncologic operations (pancreatectomy, hepatectomy, retroperitoneal sarcoma resection, nephrectomy, or cytoreductive surgery for ovarian cancer) with curative intent and have a planned postoperative inpatient stay of at least 48 hours will be eligible. Patients will be stratified by their managing clinical service and randomized to receive a discharge opioid prescription based on either the 5x-multiplier algorithm or the 3-tier model. The co-primary outcomes are initial discharge OME volume and OME consumption in the 14 days after hospital discharge. Secondary outcomes include rates of patients with zero OME at discharge; rates of refill requests and completions, number of unused or leftover pills, persistent opioid use, and patient-reported quality-of-life metrics at various follow-up times; patient, prescriber, and oncologic factors predictive of persistent opioid use; and patient satisfaction. Each co-primary endpoint will be analyzed using two-sample t-test to compare means and linear regression models to assess differences between the two arms. Ethics and Dissemination This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (2023-0818). The study will evaluate the difference in initial discharge OME volume and in 14-day post-discharge OME consumption between two discharge opioid prescribing models. Upon completion of the data collection and analyses, a manuscript describing the study results will be submitted to a peer-reviewed journal for publication and dissemination. Trial Registration Number: NCT06232577.Keywords
This publication has 26 references indexed in Scilit:
- Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung CancerJAMA Oncology, 2018
- Spillover Effect of Evidence-Based Postoperative Opioid PrescribingJournal of the American College of Surgeons, 2018
- Correlation Between 24-Hour Predischarge Opioid Use and Amount of Opioids Prescribed at Hospital DischargeJAMA Surgery, 2018
- New Persistent Opioid Use Among Patients With Cancer After Curative-Intent SurgeryJournal of Clinical Oncology, 2017
- Wide Variation and Overprescription of Opioids After Elective SurgeryAnnals of Surgery, 2017
- Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015MMWR. Morbidity and Mortality Weekly Report, 2017
- Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014MMWR. Morbidity and Mortality Weekly Report, 2016
- Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–20102012
- Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.2011
- Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI‐GI)Cancer, 2010